Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MDM2 mutation
i
Other names:
MDM2, HDM2, MGC5370, MDM2 proto-oncogene, E3 ubiquitin protein ligase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4193
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436)
Phase 1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Active, not recruiting
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
04/18/2024
Initiation :
01/24/2019
Primary completion :
04/30/2025
Completion :
04/30/2025
HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A
|
ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification
|
paclitaxel • ALRN-6924
SGT-53 in Children With Recurrent or Progressive CNS Malignancies (NCT03554707)
Phase 1
SynerGene Therapeutics, Inc.
SynerGene Therapeutics, Inc.
Not yet recruiting
Phase 1
SynerGene Therapeutics, Inc.
Not yet recruiting
Last update posted :
02/08/2022
Initiation :
06/01/2022
Primary completion :
12/01/2023
Completion :
12/01/2024
MGMT • MDM2 • CDKN1A
|
ATRX mutation • MDM2 mutation
|
Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login